Stock Events

Stock Events

0913693 B.C. 

$0
1
-$0.04-99.75% Monday 16:11

Statistics

Day High
0.04
Day Low
0.04
52W High
0.04
52W Low
0
Volume
550
Avg. Volume
3,820
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6MayExpected
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2024
Q1 2025
-0.04
-0.03
-0.02
-0.01
Expected EPS
N/A
Actual EPS
N/A

Financials

-37.17%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
257,179.42Revenue
-95,599.93Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow REPCF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. develops treatments in various medical fields, including dermatology, potentially overlapping with Replicel's skin and hair regeneration products.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. works on regenerative medicine and could compete in developing similar treatments as Replicel.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals Incorporated engages in cell therapies, a field closely related to Replicel's regenerative medicine technologies.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical Inc. offers therapies for rare genetic diseases, potentially competing in the regenerative medicine space.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics, Inc. focuses on genomic medicine, which could intersect with Replicel's technology in genetic and cellular therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals, Inc. develops RNAi therapeutics, which could compete with Replicel's cellular based therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG focuses on gene editing, a technology that could be used in competing directly with Replicel's regenerative medicine products.

About

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Andrew Schutte
Country
US
ISIN
CA9889361007

Listings

OTC Link
US
REPCF

0 Comments

Share your thoughts

FAQ

What is 0913693 B.C. stock price today?▼
The current price of REPCF is $0 USD — it has decreased by -99.75% in the past 24 hours. Watch 0913693 B.C. stock price performance more closely on the chart.
What is 0913693 B.C. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange 0913693 B.C. stocks are traded under the ticker REPCF.
Is 0913693 B.C. stock price growing?▼
REPCF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year 0913693 B.C. has showed a -95% decrease.
What is 0913693 B.C. revenue for the last year?▼
0913693 B.C. revenue for the last year amounts to 257,179.42 USD.
What is 0913693 B.C. net income for the last year?▼
REPCF net income for the last year is -95,599.93 USD.
In which sector is 0913693 B.C. located?▼
0913693 B.C. operates in the Health Care sector.
When did 0913693 B.C. complete a stock split?▼
The last stock split for 0913693 B.C. was on August 10, 2016 with a ratio of 1:10.
Where is 0913693 B.C. headquartered?▼
0913693 B.C. is headquartered in Vancouver, US.